Trial · NCT00148954

RIGHT: Rhythm ID Going Head-to-Head Trial

NCT00148954, Phase 4, Completed, Boston Scientific Corporation; results first posted 2011-12-26

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. RIGHT: Rhythm ID Going Head-to-Head Trial. Trials, record NCT00148954. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00148954

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: RIGHT: Rhythm ID Going Head-to-Head Trial
NCT number: NCT00148954
Status: Completed
Phases: Phase 4
Enrollment: 1,962 participants, actual
Lead sponsor: Boston Scientific Corporation
Conditions: Tachycardia
Interventions: VITALITY 2 Implantable Cardioverter Defibrillator, Medtronic Implantable Cardioverter Defibrillator
First posted: 2005-09-08
Last updated: 2012-01-12
Results first posted: 2011-12-26

Source ClinicalTrials.gov

Registered outcomes4

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Number of Patients With Inappropriate Ventricular Tachycardia (VT)/Ventricular Fibrillation (VF) Therapy (Shock or Antitachycardia Pacing [ATP]) After the Pre-Discharge Visit	From date of pre-discharge until a minimum of 12 months follow-up until study closure	An inappropriate therapy is defined as a VT/VF therapy, either shock or antitachycardia pacing (ATP), delivered for a supraventricular tachycardia (SVT). All events for which a VT/VF therapy was delivered and a stored electrogram exists were reviewed by an independent adjudication committee to determine the appropriateness of device rhythm classification and subsequent therapy delivery.
Secondary	Time to First Inappropriate Shock Using VITALITY and Selected Medtronic Implantable Cardioverter Defibrillator (ICDs)	Time of event
Secondary	Positive Predictive Value (PPV) of Ventricular Tachycardia/Fibrillation (VT/VF) Discrimination Algorithms Found in VITALITY 2 and Medtronic Implantable Cardioverter Defibrillators (ICDs)	Time of event
Secondary	Time to First Inappropriate Therapy for Which the Discrimination Algorithm Found in VITALITY 2 and Medtronic Implantable Cardioverter Defibrillator (ICDs) Inappropriately Classified the Episode	Time of event

Source ClinicalTrials.gov

Outcomes4

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Number of Patients With Inappropriate Ventricular Tachycardia (VT)/Ventricular Fibrillation (VF) Therapy (Shock or Antitachycardia Pacing [ATP]) After the Pre-Discharge Visit	From date of pre-discharge until a minimum of 12 months follow-up until study closure	Participants	NUMBER
SECONDARY	Time to First Inappropriate Shock Using VITALITY and Selected Medtronic Implantable Cardioverter Defibrillator (ICDs)	Time of event
SECONDARY	Positive Predictive Value (PPV) of Ventricular Tachycardia/Fibrillation (VT/VF) Discrimination Algorithms Found in VITALITY 2 and Medtronic Implantable Cardioverter Defibrillators (ICDs)	Time of event
SECONDARY	Time to First Inappropriate Therapy for Which the Discrimination Algorithm Found in VITALITY 2 and Medtronic Implantable Cardioverter Defibrillator (ICDs) Inappropriately Classified the Episode	Time of event

Source ClinicalTrials.gov

Results by group2

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Number of Patients With Inappropriate Ventricular Tachycardia (VT)/Ventricular Fibrillation (VF) Therapy (Shock or Antitachycardia Pacing [ATP]) After the Pre-Discharge Visit	VITALITY 2		246		Participants
Number of Patients With Inappropriate Ventricular Tachycardia (VT)/Ventricular Fibrillation (VF) Therapy (Shock or Antitachycardia Pacing [ATP]) After the Pre-Discharge Visit	Medtronic Family		187		Participants

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	VITALITY 2	985
Overall Study	STARTED	Medtronic Family	977
Overall Study	COMPLETED	VITALITY 2	678
Overall Study	COMPLETED	Medtronic Family	677
Overall Study	NOT COMPLETED	VITALITY 2	307
Overall Study	NOT COMPLETED	Medtronic Family	300

Source ClinicalTrials.gov

Adverse events12

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Pulse generator Related	Cardiac disorders	VITALITY 2	33	985	33
other	Pulse generator Related	Cardiac disorders	Medtronic Family	21	977	21
other	Right atrial lead related	Cardiac disorders	VITALITY 2	18	985	25
other	Right atrial lead related	Cardiac disorders	Medtronic Family	11	977	11
other	Right ventricular lead related	Cardiac disorders	VITALITY 2	48	985	57
other	Right ventricular lead related	Cardiac disorders	Medtronic Family	60	977	77
other	Procedure related	Cardiac disorders	VITALITY 2	30	985	32
other	Procedure related	Cardiac disorders	Medtronic Family	25	977	26
other	Cardiovascular related	Cardiac disorders	VITALITY 2	410	985	769
other	Cardiovascular related	Cardiac disorders	Medtronic Family	373	977	690

1 to 10 of 12Source ClinicalTrials.gov

See all 12 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	VITALITY 2
Total, all-cause mortality	Medtronic Family
Total, other adverse events	VITALITY 2	535	985
Total, other adverse events	Medtronic Family	508	977
Total, serious adverse events	VITALITY 2	0	0
Total, serious adverse events	Medtronic Family	0	0

Source ClinicalTrials.gov

Papers2

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
16836672	RESULT	PubMed
21978966	DERIVED	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons1

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison
VITALITY 2 vs Medtronic Family: Number of Patients With Inappropriate Ventricular Tachycardia (VT)/Ventricular Fibrillation (VF) Therapy (Shock or Antitachycardia Pacing [ATP]) After the Pre-Discharge Visit

Source Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00148954

GET https://conductscience.org/api/trials/v1/NCT00148954/registered

API reference For AI assistants